Last reviewed · How we verify
NB
NB (naltrexone/bupropion) is a combination drug that reduces appetite and increases energy expenditure through opioid antagonism and norepinephrine/dopamine reuptake inhibition.
NB (naltrexone/bupropion) is a combination drug that reduces appetite and increases energy expenditure through opioid antagonism and norepinephrine/dopamine reuptake inhibition. Used for Chronic weight management in obese or overweight adults with weight-related comorbidities.
At a glance
| Generic name | NB |
|---|---|
| Sponsor | Orexigen Therapeutics, Inc |
| Drug class | Combination antiobesity agent (opioid antagonist + norepinephrine-dopamine reuptake inhibitor) |
| Target | Opioid receptors (naltrexone); norepinephrine and dopamine transporters (bupropion) |
| Modality | Small molecule |
| Therapeutic area | Obesity / Metabolic Disease |
| Phase | FDA-approved |
Mechanism of action
Naltrexone blocks opioid receptors in the hypothalamus, removing tonic inhibition of pro-opiomelanocortin (POMC) neurons that regulate appetite. Bupropion, an atypical antidepressant, inhibits reuptake of norepinephrine and dopamine, further enhancing satiety signaling and metabolic rate. Together, these mechanisms reduce hunger and increase energy expenditure, leading to weight loss.
Approved indications
- Chronic weight management in obese or overweight adults with weight-related comorbidities
Common side effects
- Nausea
- Constipation
- Headache
- Dizziness
- Vomiting
- Insomnia
- Dry mouth
Key clinical trials
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (PHASE2, PHASE3)
- Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma (PHASE1)
- Atorvastatin in Active Vitiligo (PHASE2)
- PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PHASE1)
- A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma (PHASE2)
- Short-term Comparative Clinical Outcomes of Acupuncture and Phototherapy in Chronic Generalized Pruritus (NA)
- Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo (PHASE2)
- Phototherapy and Mogamulizumab in Early Stage MF (PLIGHT) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |